Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MRCG | Derived | EUR | Real-time | |
MRCG | Xetra | EUR | Delayed | |
MRKd | BATS Europe | EUR | Delayed | |
MKKGY | OTC Markets | USD | Delayed | |
0O14 | London | EUR | Real-time | |
MRCG | Milan | EUR | Real-time | |
MRCG | TradeGate | EUR | Delayed | |
MRCG | Frankfurt | EUR | Delayed | |
MRCG | Vienna | EUR | Real-time |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.
Name | Age | Since | Title |
---|---|---|---|
Michael Kleinemeier | 66 | 2019 | Independent Chairman of Supervisory Board |
Sascha Held | 42 | 2019 | Vice Chair of Supervisory Board |
Barbara Lambert | 62 | 2023 | Independent Member of Supervisory Board |
Alexander Putz | 58 | 2020 | Member of Supervisory Board |
Dietmar Oeter | 58 | 2014 | Independent Member of Supervisory Board |
Simon Thelen | - | 2019 | Independent Member of Supervisory Board |
Anne Lange | - | 2019 | Independent Member of Supervisory Board |
Christian Raabe | - | 2019 | Independent Member of Supervisory Board |
Daniel Thelen | - | 2019 | Independent Member of Supervisory Board |
Carla Kriwet | 53 | 2024 | Supervisory Board Member |
Birgit Biermann | 51 | 2022 | Member of Supervisory Board |
Katja Garcia Vila | 52 | 2024 | Supervisory Board Member |
Susanne Schaffert | 57 | 2024 | Supervisory Board Member |
Michael Reinhart | 45 | 2024 | Supervisory Board Member |
Stefan Palzer | 55 | 2024 | Supervisory Board Member |
Sandra Schwebke | 53 | 2024 | Supervisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review